ICU Medical Yönetim

Yönetim kriter kontrolleri 2/4

ICU Medical CEO'su Vivek Jain, Feb2014 tarihinde atandı, in görev süresi 10.75 yıldır. in toplam yıllık tazminatı $ 6.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11.4% maaş ve 88.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.79% ine doğrudan sahiptir ve bu hisseler € 31.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.8 yıl ve 6.8 yıldır.

Anahtar bilgiler

Vivek Jain

İcra Kurulu Başkanı

US$6.8m

Toplam tazminat

CEO maaş yüzdesi	11.4%
CEO görev süresi	10.8yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Vivek Jain'un ücretlendirmesi ICU Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$111m
Jun 30 2024	n/a	n/a	-US$71m
Mar 31 2024	n/a	n/a	-US$59m
Dec 31 2023	US$7m	US$775k	-US$30m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$6m	US$756k	-US$74m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	US$5m
Mar 31 2022	n/a	n/a	US$41m
Dec 31 2021	US$5m	US$650k	US$103m
Sep 30 2021	n/a	n/a	US$109m
Jun 30 2021	n/a	n/a	US$103m
Mar 31 2021	n/a	n/a	US$94m
Dec 31 2020	US$3m	US$650k	US$87m
Sep 30 2020	n/a	n/a	US$81m
Jun 30 2020	n/a	n/a	US$83m
Mar 31 2020	n/a	n/a	US$87m
Dec 31 2019	US$3m	US$650k	US$101m
Sep 30 2019	n/a	n/a	US$73m
Jun 30 2019	n/a	n/a	US$47m
Mar 31 2019	n/a	n/a	US$55m
Dec 31 2018	US$6m	US$650k	US$29m
Sep 30 2018	n/a	n/a	US$86m
Jun 30 2018	n/a	n/a	US$86m
Mar 31 2018	n/a	n/a	US$18m
Dec 31 2017	US$4m	US$650k	US$69m

Tazminat ve Piyasa: Vivek 'nin toplam tazminatı ($USD 6.81M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.90M ).

Tazminat ve Kazançlar: Vivek şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Vivek Jain (52 yo)

10.8yrs

Görev süresi

US$6,810,975

Tazminat

Mr. Vivek Jain has been an Independent Director of Envista Holdings Corporation since April 07, 2020. Mr. Jain has been Chairman and Chief Executive Officer of ICU Medical, Inc. since February 13, 2014. Mr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vivek Jain	CEO & Chairman of the Board	10.8yrs	US$6.81m	0.79% € 31.3m
Daniel Woolson	President	less than a year	US$2.21m	0.054% € 2.1m
Brian Bonnell	CFO & Treasurer	4.7yrs	US$4.39m	0.10% € 4.0m
Christian Voigtlander	Chief Operating Officer	6.8yrs	US$4.40m	Veri yok
Virginia Sanzone	Corporate VP	6.8yrs	US$2.47m	0.018% € 725.2k

6.8yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: IC7 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vivek Jain	CEO & Chairman of the Board	10.8yrs	US$6.81m	0.79% € 31.3m
Elisha Finney	Independent Director	8.8yrs	US$265.14k	0.0087% € 344.6k
Kolleen Kennedy	Independent Director	2.9yrs	US$255.14k	0.0064% € 252.7k
David Hoffmeister	Independent Director	6.8yrs	US$282.14k	0.012% € 489.6k
Laurie Hernandez	Independent Director	3.3yrs	US$255.14k	0.0077% € 305.0k
David Greenberg	Lead Independent Director	9.3yrs	US$296.14k	0.023% € 895.6k
Donald Abbey	Independent Director	6.8yrs	US$255.14k	0.012% € 489.6k

6.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IC7 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

ICU Medical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

ICU Medical, Inc. Appoints Daniel Woolson as President

Insider recently sold €369k worth of stock

Insufficient new directors

Chief Operating Officer recently sold €1.2m worth of stock

ICU Medical, Inc., Annual General Meeting, May 15, 2024

ICU Medical, Inc. Announces the Resignation of Bill Seeger as Nominated Director

Recent updates

Third quarter 2024 earnings released: US$1.35 loss per share (vs US$0.30 profit in 3Q 2023)

ICU Medical, Inc. Revises Earnings Guidance for the Year 2024

ICU Medical, Inc. Revises Earnings Guidance for the Year 2024

ICU Medical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

ICU Medical, Inc. Appoints Daniel Woolson as President

Insider recently sold €369k worth of stock

Now 22% undervalued

New minor risk - Share price stability

ICU Medical, Inc. Updates Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

ICU Medical, Inc. to Report Q2, 2024 Results on Aug 07, 2024

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell 1000 Dynamic Index

Chief Operating Officer recently sold €1.2m worth of stock

First quarter 2024 earnings released: US$1.63 loss per share (vs US$0.41 loss in 1Q 2023)

ICU Medical, Inc. Provides Updated Unaudited Earnings Guidance for the Year 2024

ICU Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

ICU Medical, Inc., Annual General Meeting, May 15, 2024

ICU Medical, Inc. Announces the Resignation of Bill Seeger as Nominated Director

Chief Operating Officer recently sold €1.3m worth of stock

ICU Medical, Inc. Announces Resignation of William Seeger from Board of Director and Member of the Audit and Compliance Committee

Full year 2023 earnings released: US$1.23 loss per share (vs US$3.11 loss in FY 2022)

ICU Medical, Inc. to Report Q4, 2023 Results on Feb 27, 2024

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from S&P 400 Health Care (Sector)

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$0.30 (vs US$0.55 loss in 3Q 2022)

ICU Medical, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Operating Officer recently sold €825k worth of stock

ICU Medical Inc. Receives FDA Clearance for Plum Duo Infusion Pump and LifeShield Infusion Safety Software

Icu Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: US$0.41 loss per share (vs US$0.31 loss in 2Q 2022)

ICU Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell Small Cap Comp Growth Index

First quarter 2023 earnings released: US$0.41 loss per share (vs US$1.61 loss in 1Q 2022)

Now 20% undervalued after recent price drop

Full year 2022 earnings released: US$3.11 loss per share (vs US$4.86 profit in FY 2021)

ICU Medical, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.47 profit in 3Q 2021)

ICU Medical, Inc. Reaffirms Earnings Guidance for the Full Year 2022

ICU Medical, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$1.34 profit in 2Q 2021)

ICU Medical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Corporate VP recently sold €125k worth of stock

First quarter 2022 earnings released: US$1.61 loss per share (vs US$1.12 profit in 1Q 2021)

ICU Medical, Inc. to Report Q1, 2022 Results on May 09, 2022

ICU Medical, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ICU Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2022

ICU Medical, Inc. Announces Executive changes, Effective March 18, 2022

ICU Medical, Inc. to Report Q4, 2021 Results on Feb 24, 2022

ICU Medical, Inc. Announces Appointment of William Seeger as Director, Member of Audit and Compliance Committee

ICU Medical, Inc. (NasdaqGS:ICUI) completed the acquisition of Smiths Medical, Inc. from Smiths Group plc (LSE:SMIN).

Insufficient new directors

Third quarter 2021 earnings released: EPS US$1.47 (vs US$1.19 in 3Q 2020)

Corporate VP recently sold €170k worth of stock

Investor sentiment improved over the past week

ICU Medical, Inc. (NasdaqGS:ICUI) entered into an agreement to acquire Smiths Medical Division from Smiths Group plc (LSE:SMIN) for $2.5 billion.

ICU Medical, Inc. Issues Voluntary Nationwide Recall of Aminosyn II 15%, an Amino Acid Injection, Sulfite Free IV Solution Due to the Presence of Particulate Matter

ICU Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Second quarter 2021 earnings released: EPS US$1.34 (vs US$0.91 in 2Q 2020)

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell 1000 Growth Index

Independent Director recently sold €251k worth of stock

Corporate VP recently sold €162k worth of stock

First quarter 2021 earnings released: EPS US$1.12 (vs US$0.81 in 1Q 2020)

Independent Director recently sold €257k worth of stock

Full year 2020 earnings released: EPS US$4.16 (vs US$4.90 in FY 2019)

ICU Medical, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €178

New 90-day high: €174

Revenue beats expectations